BridgeBio Oncology Therapeutics, Inc.
Company Stats
- Market Cap
- $328.7M
- as of Sep 30, 2026
- Shares Outstanding
- 80.2M
- Free Float
- 23.9%
Income Statement
- Operating Income
- -$145.8M
- Net Income
- -$134.0M
- EBITDA
- -$145.5M
Cash Flow
- Free Cash Flow
- -$114.5M
- FCF Yield
- -34.8%
- Owner FCF Yield
- -36.6%
Balance Sheet
- Cash & Equivalents
- $373.7M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | — | -$114.5M | — |
| FY2024 | — | -$55.1M | — |
Annual filing data through FY ended December 31, 2025; shares and float as of October 14, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges